Last reviewed · How we verify

ALT-803 — Competitive Intelligence Brief

ALT-803 (ALT-803) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-15 superagonist. Area: Oncology.

phase 2 IL-15 superagonist IL-15 receptor complex Oncology Biologic Live · refreshed every 30 min

Target snapshot

ALT-803 (ALT-803) — ImmunityBio, Inc.. ALT-803 is an IL-15 superagonist that stimulates the expansion of natural killer cells and CD8+ T cells.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ALT-803 TARGET ALT-803 ImmunityBio, Inc. phase 2 IL-15 superagonist IL-15 receptor complex
N-803 N-803 National Cancer Institute (NCI) phase 3 IL-15 superagonist IL-15 receptor (IL-15R)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-15 superagonist class)

  1. ImmunityBio, Inc. · 1 drug in this class
  2. National Cancer Institute (NCI) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ALT-803 — Competitive Intelligence Brief. https://druglandscape.com/ci/alt-803. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: